Hydroxyproline Influence on Oxalate Metabolism

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

September 30, 2016

Study Completion Date

January 31, 2017

Conditions
Hyperoxaluria
Interventions
DRUG

Hydroxyproline and Leucine

Subjects will be infused with 13C5-hydroxyproline and 2H3-leucine for 6 hrs in the CRTU. The metabolic flux of 2H3-leucine has been well characterized, and is used as a control when studying the metabolism of trace infusions of labeled amino acids 3. Blood samples will be obtained every 30 min to determine the enrichment of plasma with 13C5-hydroxyproline and 2H3-leucine. Urine collections will be obtained hourly. The fluxes of whole body hydroxyproline and leucine will be calculated

Trial Locations (1)

55905

Mayo Clinic Hyperoxaluria Center, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

Rare Diseases Clinical Research Network

NETWORK

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Mayo Clinic

OTHER